# Eiry Roberts

> Eiry W. Roberts, M.D., is a physician, pharmaceutical R&D executive and board director whose career spans clinical pharmacology, portfolio governance and late-stage development. After 26 years at Eli Lilly, she served seven years as Neurocrine Biosciences' chief medical officer, moved into a strategic advisory role in 2025, and now also serves on the boards of Amicus Therapeutics and Bausch Health.

- **Role:** Strategic Advisor to the CEO at Neurocrine Biosciences
- **Organizations:** Neurocrine Biosciences, Eli Lilly and Company, Amicus Therapeutics, Bausch Health Companies, Indiana University
- **Education:** M.D.; training in pharmacology and medicine, University of London, Postgraduate clinical training in clinical pharmacology and cardiology, St. Bartholomew's Hospital and Royal London Hospital, M.R.C.P.; Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians of the United Kingdom
- **Known for:** Built Neurocrine's clinical development team and broadened its internal development capabilities, according to the company's CEO., Led Neurocrine indication-expansion work for valbenazine and the crinecerfont program through a U.S. regulatory approval., Oversaw successful Phase 2 proof-of-concept studies for osavampator and NBI-1117568 before both moved toward registrational programs.

## Career timeline

- **1987** — Qualified in medicine from the University of London.
- **1991-2017** — Spent 26 years at Eli Lilly and Company, advancing through clinical pharmacology, product development and senior R&D roles.
- **2018-01** — Joined Neurocrine Biosciences as chief medical officer, leading clinical development and medical affairs.
- **2021-06** — Joined the board of directors of Amicus Therapeutics.
- **2025-06** — Transitioned from chief medical officer to strategic adviser to Neurocrine's CEO.
- **2025-11** — Neurocrine extended her strategic advisory term through December 31, 2026.
- **2026-05** — Elected to the Bausch Health board and appointed chair of its Science and Technology Committee.

## Achievements

- Built Neurocrine's clinical development team and broadened its internal development capabilities, according to the company's CEO.
- Led Neurocrine indication-expansion work for valbenazine and the crinecerfont program through a U.S. regulatory approval.
- Oversaw successful Phase 2 proof-of-concept studies for osavampator and NBI-1117568 before both moved toward registrational programs.
- At Eli Lilly, established a therapeutic area that advanced five potential medicines from Phase 1 toward approval, with two receiving regulatory approval.
- Chaired Eli Lilly's Medical Review Committee and served on corporate portfolio management and venture steering committees.
- Elected to the Bausch Health board in 2026 and named chair of its Science and Technology Committee.

## Latest updates

- **2026-05** — Bausch Health shareholders elected Roberts as a new director; the company appointed her chair of the Science and Technology Committee.
- **2025-11** — Neurocrine extended Roberts's strategic advisory role through December 31, 2026.
- **2025-06** — Roberts transitioned from Neurocrine chief medical officer to strategic adviser to the CEO.

## Links

- Website: https://neurocrine.com
- LinkedIn: https://www.linkedin.com/in/eiry-roberts-md-6b3bab54

---

Profile page: https://yespress.io/eiry-roberts
Published by YesPress — https://yespress.io
Last updated: 2026-08-21